{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:18:55Z","timestamp":1772165935957,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-026-02053-0","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T04:54:17Z","timestamp":1768625657000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic significance of neuroendocrine differentiation and PD-L1 expression in treatment-na\u00efve prostate cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Ilkay","family":"Tosun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onur","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130rem G\u00fcvendir","family":"Bakkalo\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurullah Mustafa","family":"\u015ei\u015fik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melike","family":"\u00d6z\u00e7elik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"issue":"3","key":"2053_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.31491\/UTJ.2023.09.010","volume":"7","author":"F Greco","year":"2023","unstructured":"Greco F, Domanico L, Inferrera A, Gozo M, Lembo F. Neuroendocrine prostate tumors: histologic features and therapy. Uro-Technol J. 2023;7(3):18\u201325.","journal-title":"Uro-Technol J"},{"issue":"3","key":"2053_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12032-021-01473-2","volume":"38","author":"E Abdulfatah","year":"2021","unstructured":"Abdulfatah E, Reichert ZR, Davenport MS, Chinnaiyan AM, Dadhania V, Wang X, et al. De Novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome. Med Oncol Northwood Lond Engl. 2021;38(3):26.","journal-title":"Med Oncol Northwood Lond Engl"},{"issue":"S1","key":"2053_CR3","first-page":"S122","volume":"31","author":"SW Fine","year":"2018","unstructured":"Fine SW. Neuroendocrine tumors of the prostate. Mod Pathol Off J U S Can Acad Pathol Inc. 2018;31(S1):S122\u2013132.","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"issue":"4","key":"2053_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/JCMA.0000000000001209","volume":"88","author":"JI Lai","year":"2025","unstructured":"Lai JI, Peng YC, Chang PMH, Chang YH, Chung HJ, Huang YH, et al. Real-world experience in treatment outcome and genomic insights for metastatic prostate neuroendocrine carcinoma. J Chin Med Assoc. 2025;88(4):283.","journal-title":"J Chin Med Assoc"},{"issue":"13","key":"2053_CR5","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.12998\/wjcc.v12.i13.2143","volume":"12","author":"M Wishahi","year":"2024","unstructured":"Wishahi M. Treatment-induced neuroendocrine prostate cancer and de Novo neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factors. World J Clin Cases. 2024;12(13):2143\u20136.","journal-title":"World J Clin Cases"},{"key":"2053_CR6","doi-asserted-by":"crossref","unstructured":"Urban RQ, Keerthikumar S, Clark A, Wang H, Phipson B, Bakshi A et al. Defining focal neuroendocrine differentiation as a transcriptionally distinct form of prostate cancer pathology characterized by the expression of androgen receptors. bioRxiv; 2024. p. 2024.03.17.585125. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/2024.03.17.585125v1. Cited 4 May 2025.","DOI":"10.1101\/2024.03.17.585125"},{"key":"2053_CR7","doi-asserted-by":"publisher","first-page":"102992","DOI":"10.1016\/j.critrevonc.2020.102992","volume":"151","author":"C Buonerba","year":"2020","unstructured":"Buonerba C, Ferro M, Dolce P, Crocetto F, Verde A, Lucarelli G, et al. Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020;151:102992.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2053_CR8","doi-asserted-by":"publisher","first-page":"103198","DOI":"10.1016\/j.critrevonc.2020.103198","volume":"157","author":"M Ferro","year":"2021","unstructured":"Ferro M, Lucarelli G, Crocetto F, Dolce P, Verde A, La Civita E, et al. First-line systemic therapy for metastatic castration-sensitive prostate cancer: an updated systematic review with novel findings. Crit Rev Oncol Hematol. 2021;157:103198.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2053_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.humpath.2024.02.012","volume":"145","author":"YH Ho","year":"2024","unstructured":"Ho YH, Hsu CY, Yau Li AF, Liang WY. Colorectal neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm: prognostic factors and PD-L1 expression. Hum Pathol. 2024;145:80\u20135.","journal-title":"Hum Pathol"},{"issue":"10","key":"2053_CR10","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.3390\/jcm12103362","volume":"12","author":"Z Huang","year":"2023","unstructured":"Huang Z, Tang Y, Wei Y, Qian J, Kang Y, Wang D, et al. Prognostic significance of chromogranin A expression in the initial and second biopsies in metastatic prostate cancer. J Clin Med. 2023;12(10):3362.","journal-title":"J Clin Med"},{"issue":"16","key":"2053_CR11","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1002\/pros.24791","volume":"84","author":"H Ueki","year":"2024","unstructured":"Ueki H, Jimbo N, Terakawa T, Hara T, Tobe T, Hirata J, et al. Evaluating RB1 and p53 as diagnostic markers in treatment-related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53. Prostate. 2024;84(16):1506\u201314.","journal-title":"Prostate"},{"issue":"10","key":"2053_CR12","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.3390\/cancers11101405","volume":"11","author":"GK Patel","year":"2019","unstructured":"Patel GK, Chugh N, Tripathi M. Neuroendocrine Differentiation of Prostate Cancer-An Intriguing Example of Tumor Evolution at Play. Cancers. 2019;11(10):1405.","journal-title":"Cancers"},{"issue":"5","key":"2053_CR13","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3390\/cells9051073","volume":"9","author":"R Montironi","year":"2020","unstructured":"Montironi R, Cimadamore A, Lopez-Beltran A, Scarpelli M, Aurilio G, Santoni M, et al. Morphologic, molecular and clinical features of aggressive variant prostate cancer. Cells. 2020;9(5):1073.","journal-title":"Cells"},{"issue":"24","key":"2053_CR14","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Clinical and genomic characterization of Treatment-Emergent Small-Cell neuroendocrine prostate cancer: A Multi-institutional prospective study. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(24):2492\u2013503.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"2053_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00428-012-1259-2","volume":"461","author":"SS Jeetle","year":"2012","unstructured":"Jeetle SS, Fisher G, Yang ZH, Stankiewicz E, M\u00f8ller H, Cooper CS, et al. Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer. Virchows Arch Int J Pathol. 2012;461(2):103\u20137.","journal-title":"Virchows Arch Int J Pathol"},{"issue":"8","key":"2053_CR16","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.3390\/ijms18081640","volume":"18","author":"V Genitsch","year":"2017","unstructured":"Genitsch V, Zlobec I, Seiler R, Thalmann GN, Fleischmann A. Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors. Int J Mol Sci. 2017;18(8):1640.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2053_CR17","first-page":"273","volume":"2","author":"V Parimi","year":"2014","unstructured":"Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol. 2014;2(4):273\u201385.","journal-title":"Am J Clin Exp Urol"},{"issue":"4","key":"2053_CR18","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/bju.15647","volume":"130","author":"A Kannan","year":"2022","unstructured":"Kannan A, Clouston D, Frydenberg M, Ilic D, Karim MN, Evans SM, et al. Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta-analysis. BJU Int. 2022;130(4):420\u201333.","journal-title":"BJU Int"},{"issue":"5","key":"2053_CR19","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/pros.24664","volume":"84","author":"I de Kouchkovsky","year":"2024","unstructured":"de Kouchkovsky I, Chan E, Schloss C, Poehlein C, Aggarwal R. Diagnosis and management of neuroendocrine prostate cancer. Prostate. 2024;84(5):426\u201340.","journal-title":"Prostate"},{"issue":"22","key":"2053_CR20","doi-asserted-by":"publisher","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-17-0807","volume":"23","author":"C Calagua","year":"2017","unstructured":"Calagua C, Russo J, Sun Y, Schaefer R, Lis R, Zhang Z, et al. Expression of PD-L1 in Hormone-na\u00efve and treated prostate cancer patients receiving neoadjuvant abiraterone acetate plus prednisone and leuprolide. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(22):6812\u201322.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"12","key":"2053_CR21","doi-asserted-by":"publisher","first-page":"10284","DOI":"10.18632\/oncotarget.22888","volume":"9","author":"CD Fankhauser","year":"2017","unstructured":"Fankhauser CD, Sch\u00fcffler PJ, Gillessen S, Omlin A, Rupp NJ, Rueschoff JH, et al. Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget. 2017;9(12):10284\u201393.","journal-title":"Oncotarget"},{"issue":"12","key":"2053_CR22","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.3390\/cancers12123792","volume":"12","author":"N Spetsieris","year":"2020","unstructured":"Spetsieris N, Boukovala M, Patsakis G, Alafis I, Efstathiou E. Neuroendocrine and Aggressive-Variant prostate cancer. Cancers. 2020;12(12):3792.","journal-title":"Cancers"},{"key":"2053_CR23","doi-asserted-by":"crossref","unstructured":"Novysedlak R, Guney M, Al Khouri M, Bartolini R, Koumbas Foley L, Benesova I, et al. The immune microenvironment in prostate cancer: a comprehensive review. Oncology. 2025;103(6):521\u201345.","DOI":"10.1159\/000541881"},{"key":"2053_CR24","doi-asserted-by":"publisher","first-page":"152481","DOI":"10.1016\/j.anndiagpath.2025.152481","volume":"78","author":"X Zhuang","year":"2025","unstructured":"Zhuang X, Li H, You Z, Cheng H, Guo G, Chen X, et al. PD - L1 (SP263) expression correlates with pathological aggressive parameters in prostate cancer. Ann Diagn Pathol. 2025;78:152481.","journal-title":"Ann Diagn Pathol"},{"issue":"11","key":"2053_CR25","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.3390\/cells10113166","volume":"10","author":"A Palicelli","year":"2021","unstructured":"Palicelli A, Bonacini M, Croci S, Magi-Galluzzi C, Ca\u00f1ete-Portillo S, Chaux A, et al. What do we have to know about PD-L1 expression in prostate cancer? A systematic literature Review. Part 1: focus on immunohistochemical results with discussion of Pre-Analytical and interpretation variables. Cells. 2021;10(11):3166.","journal-title":"Cells"},{"key":"2053_CR26","doi-asserted-by":"crossref","unstructured":"Matuszczak M, Salagierski M. Oligometastatic Disease in Prostate Cancer. Evolving paradigm: current knowledge, diagnostic techniques and treatment strategies. Arch Med Sci. 2022. Available from: https:\/\/www.archivesofmedicalscience.com\/Oligometastatic-Disease-in-Prostate-Cancer-Evolving-paradigm-current-knowledge-diagnostic,156170,0,2.html. Cited 1 Jan 2026.","DOI":"10.5114\/aoms\/156170"},{"key":"2053_CR27","doi-asserted-by":"crossref","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci. 2019;4(23):11428\u201336.","DOI":"10.1073\/pnas.1902651116"},{"key":"2053_CR28","doi-asserted-by":"crossref","unstructured":"Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014;38(6):756\u201367.","DOI":"10.1097\/PAS.0000000000000208"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-026-02053-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02053-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02053-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:18:30Z","timestamp":1770833910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-026-02053-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2053"],"URL":"https:\/\/doi.org\/10.1186\/s12894-026-02053-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8180352\/v1","asserted-by":"object"}]},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"22 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in line with the principles of the Declaration of Helsinki. The study protocol was approved by the Umraniye Training and Research Hospital Ethics Committee, University of Health Sciences, Istanbul, Turkey (approval number: B.10.1.TKH.4.34.H.GP.0.01\/179). Given the retrospective design of the study and the use of anonymized archival data, the requirement for written informed consent to participate was waived by the ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}